Antibody Discovery and Optimization Using Ribosome Display Antibody Presentation and Optimization Platform

Dear Colleagues,

Ribosome display technology has played a key role in the remarkable progress of discovering and optimizing antibodies for diverse applications, particularly antibody-based drugs. It is an in vitro display technology that is well suited to the selection and evolution of high-affinity antibodies. Both eukaryotic and prokaryotic translation systems have been applied to ribosome display, and the technology’s utility has been demonstrated in the antibody isolation process. In particular, ribosome display lends itself to the evolution of functional characteristics, such as potency, of lead candidate antibodies to provide therapeutic antibodies. Large libraries (up to 10¹⁵) can be rapidly constructed, antibodies selected, and sequence space extensively explored by targeted mutagenesis techniques or by random mutagenesis throughout the antibody sequence. Using such approaches in ribosome display systems leads to antibodies derived from phage display or from immunized animals, which have been improved more than 1000-fold in potency within the last 6 months. In addition, this approach (i) provides a rapid route for antibody humanization constraining the content of original mouse sequences in the final antibodies to the most hypervariable of the complementarity-determining regions (CDRs) using the CDR grafting platform; (ii) generates several humanized versions with different sequences at the same time; (iii) results in affinities as high as or higher than the affinity of the original antibody; and (iv) retains the original antibody specificity and eliminates its immunogenicity in humans. It also allows screening for antibody expression, solubility, and stability for later therapeutic development.

This Special Issue of Antibodies will consider any submission associated with ribosome display whether it be its use for discovering novel antibodies, the development of new ribosome display techniques, optimization, humanization and directed evolution approaches or its utilization in novel applications in diagnostics and therapeutics.

Prof. Adinarayana Kunamneni
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Ribosome display
• Display technologies
• Combinatorial libraries
• Biopanning
• Selection
• Humanization
• Affinity maturation
• Stability optimization
• Evolution
• Diagnostics
• Therapeutics